Skip to main content

9 Result(s)

within Charles Ng Remove this filter

and

  1. Article

    Open Access

    CRAF R391W is a melanoma driver oncogene

    Approximately 75% of melanomas have known driver oncogenic mutations in BRAF, NRAS, GNA11 or GNAQ, while the mutations providing constitutive oncogenic signaling in the remaining melanomas are not known. We es...

    Mohammad Atefi, Bjoern Titz, Jennifer Tsoi, Earl Avramis, Allison Le… in Scientific Reports (2016)

    Download PDF (3296 KB) View Article

  2. Article

    Open Access

    Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

    Approximately 20% of melanomas contain a mutation in NRAS. However no direct inhibitor of NRAS is available. One of the main signaling pathways downstream of NRAS is the MAPK pathway. In this study we investig...

    Mohammad Atefi, Bjoern Titz, Earl Avramis, Charles Ng, Deborah JL Wong… in Molecular Cancer (2015)

    Download PDF (2186 KB) View Article

  3. No Access

    Article

    Focused specificity of intestinal TH17 cells towards commensal bacterial antigens

    Segmented filamentous bacteria drive the acquisition of the TH17 phenotype in an antigen-specific manner; these findings begin to elucidate how gut-induced TH17 cells can contribute to distal organ-specific autoi...

    Yi Yang, Miriam B. Torchinsky, Michael Gobert, Huizhong **ong, Mo Xu… in Nature (2014)

  4. Article

    Open Access

    PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody

    Molecular imaging with positron emission tomography (PET) may allow the non-invasive study of the pharmacodynamic effects of agonistic monoclonal antibodies (mAb) to 4-1BB (CD137). 4-1BB is a member of the tum...

    Helena Escuin-Ordinas, Mark W Elliott… in Journal for ImmunoTherapy of Cancer (2013)

    Download PDF (1690 KB) View Article

  5. Article

    Open Access

    Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines

    TAK733 is a novel allosteric, non-ATP-binding, inhibitor of the BRAF substrates MEK-1/2.

    Erika von Euw, Mohammad Atefi, Narsis Attar, Connie Chu… in Molecular Cancer (2012)

    Download PDF (936 KB) View Article

  6. No Access

    Article

    Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance

    The development of acquired drug resistance hampers the long-term success of B-RAF inhibitor therapy for melanoma patients. Here we show V600EB-RAF copy-number gain as a mechanism of acquired B-RAF inhibitor resi...

    Hubing Shi, Gatien Moriceau, **angju Kong, Mi-Kyung Lee, Hane Lee… in Nature Communications (2012)

  7. No Access

    Article

    RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

    Although clinical trials have shown that RAF inhibitors prolong the survival of patients with BRAF-mutant melanoma, resistance inevitably develops; resistance is shown here to be frequently mediated by the exp...

    Poulikos I. Poulikakos, Yogindra Persaud, Manickam Janakiraman, **angju Kong… in Nature (2011)

  8. Article

    Open Access

    Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations

    A molecular linkage between the MAPK and the LKB1-AMPK energy sensor pathways suggests that combined MAPK oncogene inhibition and metabolic modulation of AMPK would be more effective than either manipulation a...

    Franziska Niehr, Erika von Euw, Narsis Attar… in Journal of Translational Medicine (2011)

    Download PDF (2587 KB) View Article

  9. No Access

    Reference Work Entry In depth

    Topical Drug Therapy

    Charles Ng in Encyclopedia of Pain (2007)